News Release 

Designing peptide inhibitors for possible COVID-19 treatments

American Chemical Society

Scientists across the globe are rushing to find inhibitors of SARS-CoV-2, the new coronavirus behind the COVID-19 pandemic. Some are using computer simulations to identify promising compounds before conducting actual experiments in the lab. Now, researchers reporting in ACS Nano have used computer modeling to assess four peptides that mimic the virus-binding domain of the human protein that allows SARS-CoV-2 to enter cells.

To infect cells, SARS-CoV-2 uses its spike protein to attach to the ACE2 receptor, a protein on the surfaces of certain human cells. This attachment lets the virus fuse with the host cell membrane and gain entry. Many researchers have been trying to find compounds that block key regions of the spike protein, preventing the virus from infecting cells. Yanxiao Han and Petr Král wanted to use computer modeling to design compounds that mimic the spike protein's natural target, ACE2.

To do so, the researchers examined the recently published X-ray crystal structure of the receptor-binding domain of SARS-CoV-2 when it is bound to ACE2. They identified 15 amino acids from ACE2 that interact directly with the viral protein. Then, the researchers designed four inhibitors that contain most or all of these amino acids, with additional sequences that they thought would stabilize the structures. Through computer simulations, the team studied how the inhibitors might attach to the spike protein in the body and the energies needed for binding. One of the compounds showed a particularly good fit with the viral protein. The peptide still needs to be tested in the lab and in patients, but being able to narrow down drug candidates on the computer could help expedite this process, the team says.

###

The authors acknowledge funding from the Dean's Scholar Fellowship at the University of Illinois at Chicago.

The abstract that accompanies this paper can be viewed here.

The American Chemical Society (ACS) is a nonprofit organization chartered by the U.S. Congress. ACS' mission is to advance the broader chemistry enterprise and its practitioners for the benefit of Earth and its people. The Society is a global leader in providing access to chemistry-related information and research through its multiple research solutions, peer-reviewed journals, scientific conferences, eBooks and weekly news periodical Chemical & Engineering News. ACS journals are among the most cited, most trusted and most read within the scientific literature; however, ACS itself does not conduct chemical research. As a specialist in scientific information solutions (including SciFinder® and STN®), its CAS division powers global research, discovery and innovation. ACS' main offices are in Washington, D.C., and Columbus, Ohio.

To automatically receive news releases from the American Chemical Society, contact newsroom@acs.org.

Follow us: Twitter | Facebook

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.